Media outlets do not report corporate misconduct, such as environmental offences, corruption, or violations of societal standards around human rights or employee working conditions, consistently and independently. Instead, media are often influenced by their own interests, including advertising revenues paid by offending companies.
The first presentation I wrote on the subject.
We seek to create not just work that earns pay, but meaning in what we do. Somewhere down the line, we realize that this is what advertising and brands should be about, too. Creating meaning, enabling people do things in life, making people aspire to the highest goals and showing them how to achieve it.
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...Office of Health Economics
The notion that the price of a medicine should be linked in some way to the value it generates for patients and the health system is generally accepted. Yet, how can this be achieved when, increasingly, medicines are being developed that derive patient across many different indications? We summarise the current state-of-play for indication-based pricing (IBP), both in theory as described in the key literature, and in practice by investigating its use in the US and five major European countries.
Author(s) and affiliations(s): Amanda Cole, OHE Bernarda Zamora, OHE Adrian Towse, OHE
Conference/meeting: ISPOR Europe
Event location: ISPOR Europe
Date: 13/11/2018
Media outlets do not report corporate misconduct, such as environmental offences, corruption, or violations of societal standards around human rights or employee working conditions, consistently and independently. Instead, media are often influenced by their own interests, including advertising revenues paid by offending companies.
The first presentation I wrote on the subject.
We seek to create not just work that earns pay, but meaning in what we do. Somewhere down the line, we realize that this is what advertising and brands should be about, too. Creating meaning, enabling people do things in life, making people aspire to the highest goals and showing them how to achieve it.
Should Drug Prices Differ by Indication? Outlining the debate on indication-b...Office of Health Economics
The notion that the price of a medicine should be linked in some way to the value it generates for patients and the health system is generally accepted. Yet, how can this be achieved when, increasingly, medicines are being developed that derive patient across many different indications? We summarise the current state-of-play for indication-based pricing (IBP), both in theory as described in the key literature, and in practice by investigating its use in the US and five major European countries.
Author(s) and affiliations(s): Amanda Cole, OHE Bernarda Zamora, OHE Adrian Towse, OHE
Conference/meeting: ISPOR Europe
Event location: ISPOR Europe
Date: 13/11/2018
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
Life Sciences Implications of the U.S. Affordable Care ActCognizant
Life sciences companies will see substantial changes due to the upholding of the U.S. Affordable Care Act (ACA), and we offer a map of some of the forseeable developments for drug and device manufacturers, biotechnology innovators, and others. A primer on ACA impact on revenue opportunities, earnings pressures, pricing effectiveness, compliance and business models.
Historically, the medical device industry has been highly attractive and relatively stable. As a consequence, established players have been able to compete successfully across the device spectrum, applying common business models and processes without much need for differentiation.
The future, however, is very different as disruptive change is underway. Companies will need to look at new segments and offer end-to-end solutions to secure additional revenue and maintain their profit margins.
August 19, 2021 from 1-2 pm
CORD’s LAST SUMMER webinar, Part 1 of our series on “How to Get Back to the PMPRB Original Mandate to prevent excessive drug pricing and support pharma R&D investment.” Learn why responding to the most recent (July 15th) proposed guideline changes is very important.
On August 19, 2021 from 1-2 pm, please JOIN:
Life Sciences Implications of the U.S. Affordable Care ActCognizant
Life sciences companies will see substantial changes due to the upholding of the U.S. Affordable Care Act (ACA), and we offer a map of some of the forseeable developments for drug and device manufacturers, biotechnology innovators, and others. A primer on ACA impact on revenue opportunities, earnings pressures, pricing effectiveness, compliance and business models.
Historically, the medical device industry has been highly attractive and relatively stable. As a consequence, established players have been able to compete successfully across the device spectrum, applying common business models and processes without much need for differentiation.
The future, however, is very different as disruptive change is underway. Companies will need to look at new segments and offer end-to-end solutions to secure additional revenue and maintain their profit margins.
3. BUISNESS COLLUSION
DEFINITION
A secret agreement between two or more
firm to increase or decreasing the price
of their product, rigging the market
price to reach their opportunity to be
more profitable. It also a price war
between firms.
5. EXAMPLE:
1. Shell and BP accused of collusion in South Africa
On year 2009, six companies of South Africa set up the price of diesel
artificially high to make themselves more profitable.
2. Barclays hit for LIBOR fixing
Barclays have been fined for distorting interest rates .Barclays will pay $453m for
using underhand tactics, including price-fixing, to rig the markets
3. GlaxoSmithKline fined $3 billion for off-label
GSK targeted the antidepressant Paxil at patients under age 18 when it was approved
only for adults, and promoted the drug Wellbutrin for uses it was not approved - this
tackles weight loss and treatment of sexual dysfunction.
4. Price fixing in South Korea
Samsung Electronics and LG Electronics have been fined for conspiring to fix the
prices of some appliances. The regulator said the two firms held secret meetings in
2008 and 2009 to agree on prices for some machine products.
8. NEGATIVE IMPACT OF
BUISNESS COLLUSION
•Regularly leads to reduced quality
•Harm consumers’ welfare
•Increase burden to consumers
9. - The government can enforce the laws related
to business collusion
-Persuade procurement officials to report
suspicions of collusion with strong evidence
-Increase the amount of bidders
- Preserve procurement records such as bid list
10. Individual & Public effort
-Spread through media about
business collusion
-Give advice to certain party or firm
-Give out a campaign
11. -Kuznets, P. W. (1998). Reviews. Economic Development & Cultural
Change, 47(1), 220.
-Reske, H. J. (1993). WAS IT COLLUSION OR JUST GOOD
BUSINESS?. ABA Journal, 79(5), 76.
-Drnevich, P. L., & Croson, D. C. (2013). INFORMATION TECHNOLOGY
AND BUSINESS-LEVEL STRATEGY: TOWARD AN INTEGRATED
THEORETICAL PERSPECTIVE. MIS Quarterly, 37(2), 483-509.
-Bagwell, K., & Staiger, R. W. (1997). Collusion over the business
cycle. RAND Journal Of Economics (RAND Journal Of Economics), 28(1),
82-106.
- Cook Jr., P. W. (1963). Fact and Fancy on Identical Bids. Harvard
Business Review, 41(1), 67-72.
12. -MICHIGAN BRIEFS. (2012). Crain's Detroit Business, 28(27), 0002.
-Ogawa, Y., & Ono, Y. (2011). The Byrd Amendment as Facilitating a
Tacit International Business Collusion. Review Of International
Economics, 19(5), 877-893. doi:10.1111/j.1467-9396.2011.00992.x
-Kimmons, R. (2013). Examples of Collusion Between Firms. Retrieved
from Chron: http://smallbusiness.chron.com/examples-collusionbetween-firms-18797.html